Zobrazeno 1 - 10
of 18
pro vyhledávání: '"Farzana Nazimuddin"'
Autor:
Stephan A. Grupp, David L. Porter, Carl H. June, Bruce L. Levine, Gerald Wertheim, Farzana Nazimuddin, Jason C. White, Stefan Rose-John, Zhaohui Zheng, Susan R. Rheingold, Colleen Callahan, Richard Aplenc, Robert A. Berg, Julie C. Fitzgerald, Scott L. Weiss, David M. Barrett, Jeffrey Finklestein, Fang Chen, Vanessa E. Gonzalez, Edward Pequignot, Noelle Frey, Shannon L. Maude, J. Joseph Melenhorst, Pamela A. Shaw, Simon F. Lacey, David T. Teachey
Supplementary methods, statistical methods, results, tables, and figures. Supplementary Table 1. CRS grading system. Supplementary Table 2. Samples collected and time points on the trials. Supplementary Table 3. HLH diagnostic criteria. Supplementary
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3b25964fa4b6a8e0a19d4230c9511d15
https://doi.org/10.1158/2159-8290.22532237
https://doi.org/10.1158/2159-8290.22532237
Autor:
Drew A. Torigian, Anne Marie Nelson, Michael C. Soulen, J. Joseph Melenhorst, Maureen McGarvey, Irina Kulikovskaya, Whitney L. Gladney, Fang Chen, Bruce L. Levine, Gregory L. Beatty, Mark H. O'Hara, Farzana Nazimuddin, Carl H. June, Gabriela Plesa, Simon F. Lacey
Publikováno v:
Gastroenterology. 155:29-32
Pancreatic ductal adenocarcinoma (PDAC) is resistant to T-cell mediated immunotherapy. We engineered T cells to transiently express an mRNA encoding a chimeric antigen receptor (CAR) specific for mesothelin—a protein that is over-expressed by PDAC
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d22b21460c77f4122851668b4c18eecd
https://doi.org/10.1053/j.gastro.2018.03.029
https://doi.org/10.1053/j.gastro.2018.03.029
Autor:
Vania Aikawa, Christopher A. Hunter, Miroslaw Kozlowski, Jennifer J.D. Morrissette, Michael Klichinsky, David L. Porter, Farzana Nazimuddin, David M. Barrett, John Scholler, David A. Christian, J. Joseph Melenhorst, Michael Kalos, Saar Gill, Stephan A. Grupp, Saad S. Kenderian, Carl H. June, Marco Ruella, Olga Shestova, Simon F. Lacey, Jessica Perazzelli, Ted J. Hofmann
Publikováno v:
Journal of Clinical Investigation. 126:3814-3826
Potent CD19-directed immunotherapies, such as chimeric antigen receptor T cells (CART) and blinatumomab, have drastically changed the outcome of patients with relapsed/refractory B cell acute lymphoblastic leukemia (B-ALL). However, CD19-negative rel
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6889edc833f4dd192406694746af5dcf
https://doi.org/10.1172/jci87366
https://doi.org/10.1172/jci87366
Autor:
David M. Barrett, Bruce L. Levine, Noelle V. Frey, Richard Aplenc, Pamela A. Shaw, Gerald Wertheim, Zhaohui Zheng, J. Joseph Melenhorst, Jeffrey Finklestein, Simon F. Lacey, Edward Pequignot, Susan R. Rheingold, Vanessa E. Gonzalez, Julie C. Fitzgerald, David T. Teachey, Stephan A. Grupp, Stefan Rose-John, Robert A. Berg, Jason C. White, Shannon L. Maude, David L. Porter, Carl H. June, Farzana Nazimuddin, Colleen Callahan, Fang Chen, Scott L. Weiss
Publikováno v:
Cancer Discovery. 6:664-679
Chimeric antigen receptor (CAR)–modified T cells with anti-CD19 specificity are a highly effective novel immune therapy for relapsed/refractory acute lymphoblastic leukemia. Cytokine release syndrome (CRS) is the most significant and life-threateni
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6abacb748ee1212d601cf21a4ac62c33
https://doi.org/10.1158/2159-8290.cd-16-0040
https://doi.org/10.1158/2159-8290.cd-16-0040
Autor:
Simon F. Lacey, Jamie E. DeNizio, Shantan Reddy, Rahul M. Kohli, Stefan Lundh, Irina Kulikovskaya, Jennifer J.D. Morrissette, Shelley L. Berger, Joseph A. Fraietta, Morgan A. Sammons, Yangbing Zhao, Alexandria P. Cogdill, Mercy Gohil, Marvin H. Gee, David L. Porter, Yan Wang, Enrique Lin-Shiao, Christopher L. Nobles, Xiaojun Liu, J. Joseph Melenhorst, Martha S. Jordan, David E Ambrose, Bruce L. Levine, Shannon A. Carty, Michael Kalos, Regina M. Young, Katherine A. Alexander, Frederic D. Bushman, Katherine T. Marcucci, Farzana Nazimuddin, Minnal Gupta, John K. Everett, Carl H. June, Jun Xu, K. Christopher Garcia, Fang Chen, Young Hwang, Tyler J. Reich
Cancer immunotherapy based on genetically redirecting T cells has been used successfully to treat B cell malignancies1-3. In this strategy, the T cell genome is modified by integration of viral vectors or transposons encoding chimaeric antigen recept
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f9d9594ff7433f45db65c0b1c37925dc
https://europepmc.org/articles/PMC6320248/
https://europepmc.org/articles/PMC6320248/
Autor:
Christopher L. Nobles, David M. Barrett, Regina M. Young, Carl H. June, David E Ambrose, Stephan A. Grupp, Bruce L. Levine, Prachi R. Patel, Jun Xu, Hans Bitter, Frederic D. Bushman, Irina Kulikovskaya, Farzana Nazimuddin, Olga Shestova, Simon F. Lacey, Joseph A. Fraietta, Shannon L. Maude, J. Joseph Melenhorst, Vijay Bhoj, Tyler J. Reich, Michael Klichinsky, Terry J. Fry, John Scholler, Saar Gill, Marco Ruella, Elena Orlando
Publikováno v:
Nature medicine. 24(10)
We report a patient relapsing 9 months after CD19-targeted CAR T cell (CTL019) infusion with CD19(-) leukemia that aberrantly expressed the anti-CD19 CAR. The CAR gene was unintentionally introduced into a single leukemic B cell during T cell manufac
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ce5ab317ac525c2363eeea8d09778ac6
https://pubmed.ncbi.nlm.nih.gov/30366924
https://pubmed.ncbi.nlm.nih.gov/30366924
Autor:
Vijay Bhoj, Christoph T. Ellebrecht, Gerald Wertheim, Michael C. Milone, Dimitrios Arhontoulis, Wei-Ting Hwang, S. Grupp, Shannon L. Maude, Adam Bagg, Simon F. Lacey, Amrom E. Obstfeld, Michael Feldman, Mariusz A. Wasik, Farzana Nazimuddin, J. Joseph Melenhorst, Colleen Callahan, David L. Porter, Stephen J. Schuster, James Capobianchi, Carl H. June
Publikováno v:
Blood. 128(3)
The mechanisms underlying the maintenance of long-lasting humoral immunity are not well understood. Studies in mice indicate that plasma cells (PCs) can survive up to a lifetime, even in the absence of regeneration by B cells, implying the presence o
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e96dc8dc2f03979deecf950fe9b0e908
https://pubmed.ncbi.nlm.nih.gov/27445407
https://pubmed.ncbi.nlm.nih.gov/27445407
Autor:
Beth McBride, David T. Teachey, Stephan A. Grupp, Farzana Nazimuddin, Colleen Callahan, Simon F. Lacey, Diane Baniewicz, Vanessa E. Gonzalez, Amanda M. Li, Carl H. June, Alix E. Seif, Christina Fasano, George E Hucks, David L. Porter, Amanda M. DiNofia, Shannon L. Maude
Publikováno v:
Blood. 132:556-556
Abstract CAR T cell therapy in relapsed B-ALL can result in complete response (CR) rates of 80-90%, but relapse-free survival declines to 60% within the first 12-months due to both CD19-positive and negative relapses. CD19-positive relapses that occu
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::f01caeec038a7e98a41a1026cbbb3d4e
https://doi.org/10.1182/blood-2018-99-112572
https://doi.org/10.1182/blood-2018-99-112572
Autor:
Richard Aplenc, Andreas Loew, John Scholler, Zoe Zheng, Claire White, Matthew O'Rourke, David L. Porter, Noelle Frey, Carl H. June, C. Tayor, Katherine T. Marcucci, Simon F. Lacey, Jennifer Brogdon, Susan R. Rheingold, David T. Teachey, Jeffrey Finklestein, Andrew D. Fesnak, Stephan A. Grupp, L. Lewitt, Anne Chew, M. Mudambi, Laura S Motley, Patricia A. Wood, David E Ambrose, Bruce L. Levine, C. Barker, David M. Barrett, Shannon L. Maude, Anne Lamontagne, Farzana Nazimuddin, Colleen Callahan, Pamela A. Shaw, Fang Chen, M.M. Suhoski Davis, J. Joseph Melenhorst, Regina M. Young
Publikováno v:
Cytotherapy. 18:S14-S15
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::938692c2c21c43fc4774d7816c55cab5
https://doi.org/10.1016/j.jcyt.2016.03.039
https://doi.org/10.1016/j.jcyt.2016.03.039
Autor:
Bruce L. Levine, Diane Baniewicz, Vanessa E. Gonzalez, Alix E. Seif, Farzana Nazimuddin, Colleen Callahan, Noelle V. Frey, J. Joseph Melenhorst, David T. Teachey, Stephan A. Grupp, David L. Porter, Simon F. Lacey, Shannon L. Maude, Mala K. Talekar, Carl H. June, George E Hucks, Minnal Gupta
Publikováno v:
Journal of Clinical Oncology. 35:103-103
103 Background: CD19-targeted CAR T cells show CR rates of 70-95% in B-ALL. Yet a subset of patients do not respond or relapse due to poor CAR T cell expansion and persistence. We hypothesized that PD-1 checkpoint pathway inhibition may improve CAR T
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::f4c6d2276cc35778270a7bdd4fc32a2f
https://doi.org/10.1200/jco.2017.35.15_suppl.103
https://doi.org/10.1200/jco.2017.35.15_suppl.103